SCHEMBL21499673

SCHEMBL21499673

CCCOCCOc1nc2c(c(=O)n(CCCOPI)c(=O)n2C)n1Cc1ccc(Cl)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.54
▸ MAPK1 P28482 3/20 0.54
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ TRPC4 Q9UBN4 2/20 0.50
▸ TRPC5 Q9UL62 2/20 0.50
▸ KCNH2 Q12809 1/20 0.50
▸ TRPC1 P48995 1/20 0.46
▸ MAPT P10636 3/20 0.46
▸ HIF1A Q16665 1/20 0.45
▸ KMT2A Q03164 1/20 0.44
▸ MAOA P21397 2/20 0.43
▸ MAOB P27338 2/20 0.43
▸ TSHR P16473 4/20 0.43
▸ POLB P06746 1/20 0.43
▸ LMNA P02545 3/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ TP53 P04637 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ USP2 O75604 1/20 0.42
▸ RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16076245 0.90 SMN1; SMN2 (0.60) SMN1; SMN2MAPK1L3MBTL1TRPC4TRPC5
SCHEMBL19505263 0.88 SMN1; SMN2 (0.50) SMN1; SMN2MAPK1L3MBTL1TRPC4TRPC5
SCHEMBL16028428 0.88 TRPC5 (0.64) SMN1; SMN2MAPK1L3MBTL1TRPC4TRPC5
SCHEMBL19505266 0.85 TRPC4 (0.47) SMN1; SMN2MAPK1L3MBTL1TRPC4TRPC5
SCHEMBL18833941 0.83 TRPC4 (0.47) SMN1; SMN2MAPK1L3MBTL1TRPC4TRPC5
SCHEMBL19505554 0.82 TRPC5 (0.68) SMN1; SMN2MAPK1L3MBTL1TRPC4TRPC5
SCHEMBL19505419 0.82 TRPC4 (0.49) SMN1; SMN2MAPK1TRPC4TRPC5KCNH2
SCHEMBL19505592 0.82 TRPC4 (0.49) SMN1; SMN2MAPK1TRPC4TRPC5KCNH2
SCHEMBL16028066 0.82 TRPC5 (0.68) SMN1; SMN2MAPK1L3MBTL1TRPC4TRPC5
SCHEMBL19505600 0.82 TRPC4 (0.47) SMN1; SMN2MAPK1L3MBTL1TRPC4TRPC5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230040259-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, LLC (US) 2023-02-09 — — US disclosed
US-11208409-B2 Substituted xanthines and methods of use thereof HYDRA BIOSCIENCES, LLC (US) 2021-12-28 — — US disclosed
US-20190322667-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-10-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230040259-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF TRPC5, TRPC7, TRPC4 SMN1; SMN2 1307/4885MAPK1 3995/4885L3MBTL1 1412/4885
US-11208409-B2 Substituted xanthines and methods of use thereof TRPC5, TRPC7, TRPC4 SMN1; SMN2 1307/4885MAPK1 3995/4885L3MBTL1 1412/4885
US-20190322667-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF TRPC5, TRPC7, TRPC4 SMN1; SMN2 1307/4885MAPK1 3995/4885L3MBTL1 1412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback